This challenge targets the hypothesis: **Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway** **Hypothesis Summary:** ## Mechanistic Overview Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway starts from the claim that modulating GPNMB, CD44 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The GPNMB-CD44 axis represents a complex intercellular communication network that potentially modulates neuroinflammatory responses in neurodegenerative diseases through sophisticated molecular interactions. **Falsifiable Predictions:** 1. Pharmacological modulation of GPNMB will alter neurodegeneration markers in validated models by ≥20% 2. Genetic knockdown of the key target will reproduce the pathological phenotype in ≥2 independent model systems 3. Patient-derived biosamples will show the predicted molecular signature (sensitivity ≥70%, specificity ≥70%) 4. Mechanistic intervention at the proposed node will rescue neuronal viability in vitro by ≥30% **Bounty Tier:** $127,200 USD (composite score 0.772) **Challenge Type:** Open — any team may submit experimental evidence supporting or refuting this hypothesis **Success Criteria:** Peer-reviewed evidence demonstrating mechanistic validation of ≥2 of the 4 predictions, with independent replication.